|
" Topiramate augmentation in refractory obsessive compulsive disorder: A randomized, double-blind, placebo-controlled trial "
/الهام زارعان
; Shahla Akouchekian, Hamid Afshar
| center
|
:
|
Isfahan University of Medical Sciences
|
| Document Type
|
:
|
Latin Dissertation
|
| Language of Document
|
:
|
English
|
| Record Number
|
:
|
103470
|
| Doc. No
|
:
|
T15051
|
| Call number
|
:
|
WM,176,Z36t,2014
|
| Main Entry
|
:
|
Zarean, Elham
|
| Title & Author
|
:
|
Topiramate augmentation in refractory obsessive compulsive disorder: A randomized, double-blind, placebo-controlled trial/الهام زارعان
|
| College
|
:
|
Schools, Medical
|
| Date
|
:
|
, 2014
|
| Degree
|
:
|
Psychiatry, Speciality
|
| Page No
|
:
|
21 p.: diag, tab.
|
| Note
|
:
|
This thesis is a research project with project ID:391144
|
| Abstract
|
:
|
Objective: This study aimed to assess the efficacy of Topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs). Methods: Thirty-eight patients with refractory OCD, were randomly assigned to receive Topiramate or placebo. This study was designed as a 12-week, double-blind, placebo-controlled trial. Primary outcome measures were the change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score and the rate of treatment response in each group at the study end point. Treatment response was considered as 25 percent or more reduction in Y-BOCS score. Results: 13 patients in the Topiramate group and 14 ones in the placebo group completed the trial. Topiramate-assigned patients showed significantly improved mean Y-BOCS score over time (p<0.001). Although differences between two groups was significant in the Y-BOCS score at the first two months (p=0.01), this was not significant at the end of study (p=0.10). Changes of Clinical Global Impression (CGI)-Severity of Illness scale score and CGI-Improvement scale score were not significantly different between two groups (p>0.05).Treatment response was almost significantly different in the Topiramate group comparing placebo group (p=0.054). Mean Topiramate dosage was 137.5 mg/day (range, 100-200). Conclusion: This study didn't show efficacy of Topiramate as an agent to augment SRIs in treatment-resistant OCD patients.
|
| Descriptor
|
:
|
1. Obsessive-Compulsive Disorder.- Descriptors: Obsessive-Compulsive Disorder
|
|
|
:
|
topiramate
|
|
|
:
|
therapy
|
| Added Entry
|
:
|
Akouchekian, Shahla, Supervisor
|
|
|
:
|
Afshar, Hamid, Supervisor
|
| Translated Title Supplied by Cataloguer
|
:
|
بررسی اثربخشی افزودن توپیرامات به درمان اختلال وسواسی- جبری مقاوم به درمان
|
| |